Profile data is unavailable for this security.
About the company
Liaoning Chengda Biotechnology Co Ltd is a China-based company mainly engaged in the research, production, and sales of human vaccines. The Company's main products include rabies vaccine for human use, freeze-dried rabies vaccine for human use, inactivated Japanese encephalitis vaccine for human use and freeze-dried encephalitis inactivated vaccine. The Company's products include two brands: Chengda Suda and Chengda Libao.
- Revenue in CNY (TTM)1.76bn
- Net income in CNY420.34m
- Incorporated2002
- Employees1.73k
- LocationLiaoning Chengda Biotechnology Co LtdNo. 1Xinfang Street, Hunnan New DistrictSHENYANG 110179ChinaCHN
- Phone+86 2 483782632
- Fax+86 2 423789772
- Websitehttp://www.cdbio.cn
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Runda Medical Technology Co Ltd | 9.04bn | 214.86m | 9.79bn | 3.32k | 43.94 | 2.26 | -- | 1.08 | 0.3719 | 0.3719 | 15.65 | 7.22 | 0.6219 | 4.66 | 1.56 | 2,727,524.00 | 2.55 | 4.78 | 7.04 | 12.86 | 26.02 | 27.13 | 4.10 | 6.36 | 1.06 | 7.84 | 0.5568 | 12.43 | -12.84 | 8.93 | -34.58 | 0.8514 | 3.88 | 1.03 |
| Joinn Laboratories China Co Ltd | 2.33bn | -62.99m | 10.21bn | 2.50k | -- | 1.37 | -- | 4.38 | -0.0862 | -0.0862 | 3.12 | 10.75 | 0.23 | 0.6906 | 8.14 | -- | -0.6856 | 8.99 | -0.8219 | 11.07 | 39.46 | 46.76 | -2.98 | 32.01 | 3.51 | 0.9996 | 0.0079 | 23.79 | 4.78 | 42.20 | -63.04 | 29.66 | 8.21 | 23.46 |
| Bio-Thera Solutions Ltd | 711.46m | -370.90m | 10.42bn | 1.17k | -- | 9.53 | -- | 14.65 | -0.8957 | -0.8957 | 1.72 | 2.64 | 0.3099 | 0.9439 | 6.06 | 609,647.70 | -16.15 | -23.62 | -23.70 | -30.81 | 71.41 | 79.76 | -52.13 | -106.72 | 0.8258 | -367.55 | 0.3515 | -- | 54.86 | -- | 17.87 | -- | -3.78 | -- |
| Liaoning Chengda Biotechnology Co Ltd | 1.76bn | 420.34m | 10.80bn | 1.73k | 25.58 | 1.11 | -- | 6.13 | 1.01 | 1.01 | 4.26 | 23.41 | 0.1743 | 0.7061 | 1.61 | 1,016,911.00 | 4.16 | 10.63 | 4.27 | 11.01 | 81.48 | 85.74 | 23.87 | 39.56 | 20.80 | -- | 0.002 | 31.53 | -3.58 | 4.71 | -34.75 | -5.56 | 39.78 | -- |
| Sansure Biotech Inc | 1.20bn | 384.73m | 10.85bn | 2.01k | 28.58 | 1.44 | -- | 9.02 | 0.6448 | 0.6448 | 2.06 | 12.77 | 0.1377 | 0.8274 | 1.41 | 599,646.90 | 4.14 | 26.74 | 4.69 | 30.97 | 74.82 | 67.47 | 30.06 | 42.01 | 7.94 | -- | 0.0589 | 22.40 | -84.39 | 27.12 | -81.22 | 121.89 | 64.08 | -- |
| Jiangxi Tianxin Pharmaceutical Co Ltd | 1.80bn | 514.80m | 11.06bn | 2.47k | 21.48 | 2.54 | -- | 6.15 | 1.18 | 1.18 | 4.11 | 9.95 | 0.36 | 2.68 | 6.66 | 727,792.60 | 10.31 | -- | 11.11 | -- | 39.78 | -- | 28.63 | -- | 5.51 | -- | 0.0551 | -- | -18.34 | -- | -23.51 | -- | -- | -- |
| Heilongjiang ZBD Pharmaceutical Co Ltd | 2.73bn | 511.96m | 11.23bn | 2.55k | 21.88 | 1.43 | -- | 4.12 | 0.5447 | 0.5447 | 2.90 | 8.35 | 0.2186 | 1.58 | 0.8134 | 1,071,832.00 | 4.06 | 3.48 | 5.61 | 4.78 | 46.09 | 38.93 | 18.56 | 10.08 | 2.35 | -- | 0.2862 | 27.18 | -25.50 | 2.45 | 155.00 | 0.4417 | -25.68 | 4.05 |
Data as of Jun 18 2024. Currency figures normalised to Liaoning Chengda Biotechnology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
6.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GF Securities Asset Management (Guangdong) Co., Ltd.as of 11 Mar 2024 | 2.75m | 1.54% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 2.58m | 1.44% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 2.29m | 1.28% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 881.03k | 0.49% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 738.51k | 0.41% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 620.20k | 0.35% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 595.79k | 0.33% |
| Wanjia Asset Management Co., Ltd.as of 31 Dec 2023 | 564.56k | 0.32% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 552.30k | 0.31% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2023 | 300.54k | 0.17% |
More ▼
Data from 31 Dec 2023 - 13 Jun 2024Source: FactSet Research Systems Inc.
